HIGHLIGHTS
- who: Motoyasu Miyazaki and colleagues from the Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka Department of Pharmacy, Fukuoka University Chikushi Hospital, Chikushino, Japan have published the research: Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study, in the Journal: Medicina 2022, 58, 1007. of 18/06/2022
- what: The aim of the study was to assess the efficacy and safety of RDV treatment in mildly to moderately ill patients with COVID-19. Since the homogeneity of the efficacy of RDV . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.